Kousoula Konstantina, Farmaki Katerina, Skoglund Thomas, Olsson Daniel S, Johannsson Gudmundur, Trimpou Penelope, Ragnarsson Oskar
Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Department of Endocrinology, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Gothenburg, Sweden.
Department of Neurosurgery, Sahlgrenska University Hospital, Göteborg, Sweden.
Growth Horm IGF Res. 2017 Oct;36:16-21. doi: 10.1016/j.ghir.2017.08.003. Epub 2017 Aug 24.
The suggested criteria for biochemical remission in patients treated for acromegaly were recently modified. The aim of this project was to study to what extent this modification influences remission rates.
DESIGN, PATIENTS AND METHODS: This was a retrospective study of 55 consecutive patients [29 men; median age 47years (interquartile range 38-68)] diagnosed with acromegaly between 2003 and 2014. After treatment serum IGF-I and/or GH was measured according to a standardized protocol. The biochemical remission status was defined according to the clinical guidelines from 2010 and2014.
Out of 55 patients, 44 patients were primarily operated. Of these, 33 (75%) were evaluated 3-12months postoperatively by measuring serum IGF-I and GH during an oral glucose tolerance test. According to the 2010 guidelines, 11 patients (33%) were in biochemical remission, 15 patients (46%) were not and 7 patients (21%) had discordant results (normal IGF-I and high GH or vice versa). Applying the 2014 guidelines in the same group, 16 patients (49%) were in biochemical remission, 7 patients (21%) were not and 10 patients (30%) had discordant results. Thus, by using the most recent criteria for biochemical control, more patients were considered to be in remission, or with discordant results, and fewer patients not in remission (P<0.05).
An apparently minor adjustment of the criteria for biochemical control has a significant impact on remission status in patients treated for acromegaly, eventually affecting follow-up and treatment strategies.
肢端肥大症患者生化缓解的推荐标准最近有所修改。本项目的目的是研究这种修改在多大程度上影响缓解率。
设计、患者与方法:这是一项对2003年至2014年间连续诊断为肢端肥大症的55例患者[29例男性;中位年龄47岁(四分位间距38 - 68岁)]进行的回顾性研究。治疗后,根据标准化方案测定血清IGF - I和/或生长激素(GH)。生化缓解状态根据2010年和2014年的临床指南定义。
55例患者中,44例主要接受了手术治疗。其中,33例(75%)在术后3 - 12个月通过口服葡萄糖耐量试验期间测定血清IGF - I和GH进行评估。根据2010年指南,11例患者(33%)处于生化缓解状态,15例患者(46%)未缓解,7例患者(21%)结果不一致(IGF - I正常但GH高或反之)。对同一组患者应用2014年指南时,16例患者(49%)处于生化缓解状态,7例患者(21%)未缓解,10例患者(30%)结果不一致。因此,使用最新的生化控制标准时,更多患者被认为处于缓解状态或结果不一致,而未缓解的患者更少(P<0.05)。
生化控制标准看似微小的调整对肢端肥大症患者的缓解状态有显著影响,最终会影响随访和治疗策略。